Hidradenitis Suppurativa
Conditions
Interventions
Metformin
Sponsors
ZonMw
Eligibility
Inclusion criteria
Inclusion criteria: • Age =18 years at baseline • A diagnosis of HS for at least 1 year prior to baseline • mild to moderately active disease defined by a HS Physician Global Assessment (HS-PGA) score of 2-3 and the Refined Hurley classification of mild to moderate at baseline • Indication for systemic therapy; i.e. uncontrolled disease under conventional topical therapy. • Able and willing to give written informed consent and to comply with the study requirements
Exclusion criteria
Exclusion criteria: • Pregnant and lactating women • Concomitant diabetes mellitus • Use of antibiotics within 14 days prior to baseline • Use of immunosuppressing/modulating therapies within 28 days prior to baseline • A known allergy to metformin or doxycycline or any of the ingredients metformin or doxycycline
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Insulin resistance and metabolic syndrome Clinical efficacy patient reported outcomes as NRS-pain, DLQI, Flares, treatment satisfaction and recommendation Cost-effectiveness Bio-markers Safety and Tolerability | — |
Primary
| Measure | Time frame |
|---|---|
| International Hidradenitis Suppurativa Severity Score System (IHS4) | — |
Contacts
Public ContactPim Aarts
Erasmus Medical Center
Outcome results
None listed